Sirion, Denali to develop AAVs that cross blood-brain barrier

Viral vector company Sirion Biotech GmbH (Martinsried, Germany) and neurology company Denali Therapeutics Inc. (NASDAQ:DNLI) partnered to develop adeno-associated virus (AAV) vectors that enable therapeutics to cross the blood-brain barrier to treat neurodegenerative diseases including Parkinson’s disease, Alzheimer’s disease, amyotrophic lateral sclerosis (ALS) and other CNS diseases...